SOURCE: Leerink Swann & Company

April 19, 2005 09:13 ET

Leerink Swann & Company Initiates Coverage of CV Therapeutics, Inc. (NASDAQ: CVTX)

BOSTON, MA -- (MARKET WIRE) -- April 19, 2005 -- This morning, Biotechnology Analyst Joseph P. Schwartz initiated coverage of CV Therapeutics, Inc. with an Outperform rating.

About CV Therapeutics, Inc.

CV Therapeutics, Inc. (NASDAQ: CVTX) is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases. CV Therapeutics is headquartered in Palo Alto, California.

About Leerink Swann & Company

Leerink Swann & Company is an investment banking firm that provides healthcare equity research, corporate finance, and asset management services for institutional and high-net-worth clients. Leerink Swann & Company was voted the Best Firm in Biotechnology, Medical Supplies and Devices, Pharmaceuticals/Major and Pharmaceuticals/Specialty in the December 2004 Institutional Investor poll ranking the best boutique and regional firms by sector. Through its consulting affiliate, MEDACorp, Leerink Swann & Company provides biomedical-consulting services to Life Sciences companies and to the institutional investment community. MEDACorp includes thousands of biomedical professionals and practicing physicians. Leerink Swann & Company is a member NASD/SIPC.

Contact Information

  • Contact:
    John I. Fitzgerald
    Leerink Swann & Company
    (617) 918-4564